logo

For the Inventor, By the Inventor

Paris, France

Robert Fournex

This inventor holds 15 USPTO granted patents. Top assignee: Roussel Uclaf. Active years: 1978-1985.

USPTO Granted Patents = 15

% Patents Active = 100.0

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 40(Granted Patents)


Company Filing History:

goldMedal15 out of 854 
 
Roussel Uclaf
 patents

Years Active: 1978-1985

Loading Chart...
15 patents (USPTO):Explore Patents
1. 4501740 - Blood oxygenating and cerebral vasoregulating 20,21-dinoreburnamenines (1985-02-26),
2. 4483868 - Gastro-protecting activity (1984-11-20),
3. 4450292 - Derivatives of phenyl aliphatic carboxylic acids, and use thereof in (1984-05-22),
4. 4436752 - Treatment of gastric and gastro-duodenal disorders with derivatives of (1984-03-13),
5. 4402978 - Gastro-protecting activity of substituted derivatives of (1983-09-06),
6. 4332808 - Dopaminergically stimulating 4-substituted indoles (1982-06-01),
7. 4291038 - Cerebral vasodilating 20,21-dinoreburnamenine derivatives (1981-09-22),
8. 4263290 - Novel 19-nor-steroids (1981-04-21),
9. 4258039 - Novel 7-alkyl-steroids (1981-03-24),
10. 4224333 - Antihypertensive 2H-indol-2-ones (1980-09-23),
11. 4172137 - 5-Thiazole-alkylamines used as antilipolytics (1979-10-23),
12. 4136179 - 2,2-Dimethyl-19-nor-steroids (1979-01-23),
13. 4108994 - 5-Thiazole-methane-amines, and their use as antilipolytics (1978-08-22),
14. 4078076 - Novel p-(4-tetrahydropyranyl)-phenoxy-compounds (1978-03-07),
15. 4078059 - Novel 2,2-dimethyl steroids (1978-03-07),

Title: The Innovative Contributions of Robert Fournex

Introduction

Robert Fournex is a distinguished inventor based in Paris, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with therapeutic applications. With a total of 15 patents to his name, Fournex's work has had a profound impact on medical science.

Latest Patents

Fournex's latest patents include groundbreaking research on blood oxygenating and cerebral vasoregulating compounds known as 20,21-dinoreburnamenines. These novel compounds are characterized by their unique formula, wherein R is selected from a group consisting of hydrogen, alkyl of 1 to 4 carbon atoms, and .dbd.CH.sub.2. The compounds exhibit significant oxygenating and cerebral vasoregulating activity, making them valuable in medical applications. Additionally, he has developed gastro-protecting compounds aimed at treating diseases accompanied by gastric and gastroduodenal lesions. These compounds are formulated with specific alkyl and halogen groups, showcasing Fournex's innovative approach to addressing complex health issues.

Career Highlights

Fournex has built a reputable career at Roussel Uclaf, where he has been instrumental in advancing pharmaceutical research. His dedication to innovation and excellence has positioned him as a key figure in the industry. His work not only reflects his expertise but also his commitment to improving patient outcomes through scientific advancements.

Collaborations

Fournex has collaborated with notable colleagues, including Lucien Nedelec and Francois Clemence. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances the quality of research.

Conclusion

Robert Fournex's contributions to the field of pharmaceuticals are noteworthy and impactful. His innovative patents and collaborative efforts continue to shape the landscape of medical science. His work exemplifies the importance of research and development in creating effective therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…